CMAJ • August 12, 2008; 179 (4). doi:10.1503/cmaj.071330.
© 2008 Canadian Medical Association or its licensors
All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association.
This Article
Right arrow Abstract
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Résumé
Right arrow Submit a response
Right arrow View responses
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Targownik, L. E.
Right arrow Articles by Leslie, W. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Targownik, L. E., MD MSHS
Right arrow Articles by Leslie, W. D., MD
Related Collections
Right arrow Other gastroenterology
Right arrow Osteoporosis
Right arrowRelated Articles

Use of proton pump inhibitors and risk of osteoporosis-related fractures

Laura E. Targownik, MD MSHS, Lisa M. Lix, PhD, Colleen J. Metge, PhD, Heather J. Prior, MSc, Stella Leung, MSc and William D. Leslie, MD

From the Departments of Gastroenterology (Targownik) and General Internal Medicine (Leslie), Division of Internal Medicine, the Department of Radiology (Leslie), Division of Nuclear Medicine, the Faculty of Pharmacy (Metge), and the Manitoba Centre for Health Policy, Department of Community Health Sciences, Faculty of Medicine (Targownik, Lix, Metge, Prior, Leung), University of Manitoba, Winnipeg, Man.


View this table:
[in this window]
[in a new window]

  		Table 1.

 

View this table:
[in this window]
[in a new window]

  		Table 2.

 

View this table:
[in this window]
[in a new window]

  		Table 3.

 

Figure 114
View larger version (17K):
[in this window]
[in a new window]

  		Figure 1: Association between continuous exposure to proton pump inhibitors and osteoporosis-related fractures (hip, vertebra or wrist). *Adjusted for income, region of residence, diagnoses (short-or long-term diabetes, epilepsy, ischemic heart disease, myocardial infarction, hypertension, arthritis, solid organ transplant, chronic obstructive pulmonary disease, substance use, depression, schizophrenia, dementia), home care use and multiple medications. The reference group was patients with no exposure to proton pump inhibitors or histamine-2-receptor antagonists. Note: CI = confidence interval.

 

Figure 214
View larger version (33K):
[in this window]
[in a new window]

  		Figure 2: Relation between continuous exposure to proton pump inhibitors and (A) hip and vertebral fractures and (B) hip fractures. *Adjusted for factors listed in Figure 1. Note: CI = confidence interval.